E-Scape Bio, Inc.

Founded in 2015 and based in California, US, E-Scape Bio, Inc. operates as a biopharmaceutical company. The company was founded by Yadong Huang. In September 2020, E-Scape Bio, Inc.

raised USD 73 million in Series C funding led by new investor Wellington Management, with participation from other new investors Avidity Partners, and CAM Capital. As of 2021, the company’s President and Chief Executive Officer are Julie Anne Smith. E-Scape Bio is developing small molecule drugs for the treatment of genetically defined subpopulations in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and central nervous system Lysosomal storage disorders. As of 2021, the company has three therapeutic drug candidates in its pipeline program which include ESB1609, ESB5070, and an Alzheimer's disease program.

ESB1609 is an orally administered drug that penetrates the brain and acts as a sphingosine-1-phosphate 5 (S1P5) receptor to cure neurodegenerative disease. ESB5070 is another orally administered drug that tricks the brain into blocking the action of Leucine-Rich Repeat Kinase 2 (LRRK2) G2019S protein kinases which cause partial discharge for patients. The last is a drug development program for Alzheimer's disease that could target the Apolipoprotein E allele 4 (APOE4) in the human body which is a major genetic risk factor for causing late-onset Alzheimer's disease. The company plans to advance its pipeline of precision neurology medicines into production.